CN1160454C - 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法 - Google Patents

用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法 Download PDF

Info

Publication number
CN1160454C
CN1160454C CNB998017647A CN99801764A CN1160454C CN 1160454 C CN1160454 C CN 1160454C CN B998017647 A CNB998017647 A CN B998017647A CN 99801764 A CN99801764 A CN 99801764A CN 1160454 C CN1160454 C CN 1160454C
Authority
CN
China
Prior art keywords
gly
virus
ala
ser
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998017647A
Other languages
English (en)
Chinese (zh)
Other versions
CN1287573A (zh
Inventor
石川丰数
吉井洋纪
֮
大西敏之
今川忠
石桥正英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation for Microbial Diseases of Osaka University BIKEN
Original Assignee
Research Foundation for Microbial Diseases of Osaka University BIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation for Microbial Diseases of Osaka University BIKEN filed Critical Research Foundation for Microbial Diseases of Osaka University BIKEN
Publication of CN1287573A publication Critical patent/CN1287573A/zh
Application granted granted Critical
Publication of CN1160454C publication Critical patent/CN1160454C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB998017647A 1998-10-05 1999-06-02 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法 Expired - Fee Related CN1160454C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31976298 1998-10-05
JP319762/1998 1998-10-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100473162A Division CN1618464A (zh) 1998-10-05 1999-06-02 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法

Publications (2)

Publication Number Publication Date
CN1287573A CN1287573A (zh) 2001-03-14
CN1160454C true CN1160454C (zh) 2004-08-04

Family

ID=18113906

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998017647A Expired - Fee Related CN1160454C (zh) 1998-10-05 1999-06-02 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
CNA2004100473162A Pending CN1618464A (zh) 1998-10-05 1999-06-02 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100473162A Pending CN1618464A (zh) 1998-10-05 1999-06-02 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法

Country Status (10)

Country Link
US (1) US6841374B1 (OSRAM)
EP (1) EP1057889B1 (OSRAM)
JP (2) JP4371343B2 (OSRAM)
KR (1) KR20010032699A (OSRAM)
CN (2) CN1160454C (OSRAM)
AU (1) AU743546B2 (OSRAM)
CA (1) CA2311336C (OSRAM)
MY (1) MY126520A (OSRAM)
TW (1) TWI227274B (OSRAM)
WO (1) WO2000020565A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
US7060280B2 (en) * 2003-06-11 2006-06-13 Academia Sinica Immunization against flavivirus
US7780027B2 (en) * 2007-02-08 2010-08-24 Michael Coady Axially stacked double barrel animal feeder system
BRPI0816130A2 (pt) * 2007-08-28 2015-02-24 Baxter Int Métodos para a fabricação de uma preparação e para aumentar a resistência a uma infecção viral em um indivíduo.
AU2008342194B2 (en) 2007-12-26 2014-03-20 Daiichi Sankyo Company, Limited Method of producing Japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2298344B1 (en) * 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
CN101333246B (zh) * 2008-07-30 2011-04-13 中国农业科学院哈尔滨兽医研究所 乙型脑炎病毒e蛋白中和性b细胞抗原表位多肽及其应用
CN105400798A (zh) * 2008-11-17 2016-03-16 Vgx药品有限责任公司 引起对抗黄病毒的免疫应答的抗原及其应用方法
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
CN101792741A (zh) * 2010-04-07 2010-08-04 西北农林科技大学 表达jev免疫原基因的重组杆状病毒及其制备和应用
JP6963460B2 (ja) * 2016-10-27 2021-11-10 一般財団法人阪大微生物病研究会 たん白質の定量方法
WO2021161390A1 (ja) * 2020-02-10 2021-08-19 花王株式会社 ヒトノロウイルス不活化評価法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6147185A (ja) 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6153227A (ja) 1984-08-23 1986-03-17 Biseibutsu Kagaku Kenkyusho:Kk 日本脳炎・豚パルボウイルス感染症混合生ワクチン
AT393356B (de) * 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
US5719051A (en) 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
CA2228128C (fr) 1995-08-01 2011-03-29 Pasteur Merieux Serums & Vaccins Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
US5891705A (en) 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
DE69837211T2 (de) 1997-08-28 2007-12-06 Cheil Jedang Corp. Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Also Published As

Publication number Publication date
KR20010032699A (ko) 2001-04-25
TWI227274B (en) 2005-02-01
AU4057899A (en) 2000-04-26
CA2311336C (en) 2007-01-02
CA2311336A1 (en) 2000-04-13
CN1618464A (zh) 2005-05-25
AU743546B2 (en) 2002-01-31
US6841374B1 (en) 2005-01-11
CN1287573A (zh) 2001-03-14
WO2000020565A1 (en) 2000-04-13
EP1057889A4 (en) 2002-01-23
MY126520A (en) 2006-10-31
JP2009225809A (ja) 2009-10-08
EP1057889A1 (en) 2000-12-06
EP1057889B1 (en) 2009-04-22
JP4371343B2 (ja) 2009-11-25
JP5095685B2 (ja) 2012-12-12

Similar Documents

Publication Publication Date Title
CN1884303A (zh) SARS－CoV病毒结构蛋白的融合蛋白及其高量表达与纯化和用途
CN1160454C (zh) 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
CN1440296A (zh) 抗口蹄疫疫苗
CN1492923A (zh) 减毒的活疫苗
CN1345775A (zh) 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗
CN101062952A (zh) 由人血清白蛋白和干扰素组成的融合蛋白及其编码基因与应用
CN1122108C (zh) 口蹄疫病毒的免疫原性肽
CN1255540C (zh) 一株疫苗诱导的乙型肝炎病毒株及其应用
CN1495262A (zh) gp350/220的非剪接变异体
CN1079509A (zh) 人体免疫缺陷病毒抗原
CN1990869A (zh) 鸡传染性法氏囊病病毒VP2 cDNA、其表达载体、所表达的重组蛋白及应用
CN1570115A (zh) 优化的sars冠状病毒刺突蛋白基因
CN1531548A (zh) 编码可诱导抗病毒效应的蛋白质的嵌合链
CN1281959C (zh) 烟草花叶病毒云南分离物tas－elisa检测试剂盒及其制备方法
CN1084218A (zh) 多颗粒抗原传输系统
CN1641034A (zh) 破伤风毒素重组抗原制备方法及其应用
CN1764718A (zh) 表达典型和变异ibdv株系特异性的病毒中和表位的传染性法氏囊病病毒(i bdv)突变株
HK1077509A (en) Enhanced immunogen for inactivated vaccine for infection with japaness encephalitis viruses and process for producing the same
CN101039955A (zh) 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物
CN1268392C (zh) 预防和治疗人丙型肝炎病毒感染的重组蛋白疫苗及其用途
CN1206356C (zh) 甲肝病毒中国株和减毒株的培育及互补脱氧核糖核酸序列
CN1304579C (zh) 重组的以黄热病病毒为载体的疫苗
CN1536077A (zh) 高产的重组乙型流感病毒株及其用途
CN1065142C (zh) 组合物用作慢性病毒性肝脏疾病治疗剂的应用
CN1607004A (zh) 重组口蹄疫病毒vp1融合蛋白疫苗

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040804

Termination date: 20140602